Unexpectedly, in vivo depletion of CD4+ T cells alone resulted in complete regression of EO771 tumors, while the combination of Anlotinib and anti-PD-1 therapy only slowed down EO771 tumor growth (Figure 7B). The gene discussed is CD4; the disease is neoplasm.